[Sacramento, CA] More than 1,500 people attended the APHL 2023 Annual Conference at the Sacramento Convention Center this year. Among those attendees were the Acenxion Biosystems Inc team. There, a soft announcement was made by the company about the completion of the fAST System alpha-prototype. The alpha fAST is the first fully integrated automated device […]
[Kansas City, KS] Acenxion Biosystems is pleased to announce a close on a common stock Angel round that resulted in just under $1M of unrestricted funding. Board member Brian Struchtemeyer said, “We’re extremely happy about this round as it was overwhelmingly filled by existing investors. That made my job in coordinating this round extremely easy. The […]
[Kansas City, KS] Acenxion Biosystems Inc. today announced that it was awarded a $3M SBIR Direct-to-Phase II grant by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID). The award accelerates Acenxion’s work to develop the first fully automated gonorrhea phenotypic antimicrobial sensitivity testing (AST) platform. The system will simultaneously meet […]
[Kansas City, KS] Acenxion Biosystems today announced that its seed funding round limited to existing shareholders successfully closed and exceeded expectations. “The board and I are extremely pleased with the shareholder support we received in this limited funding round. We know we have a lot more work to do both for product development and additional […]
[Kansas City, KS] Acenxion Biosystems today announced the successful execution of an exclusive patent and related IP licensing agreement with the University of Missouri (UM). Included in the license is exclusive access to: U.S. Patent No. 8,635,028 titled “Rapid Detection of Viable Bacterial System and Method” U.S. Patent No. 10,273,522 titled “Rapid Detection of Viable […]
[Kansas City, KS] Acenxion Biosystems today announced that Dr. Roy Swiger will formally be joining the company as CEO and Director effective today. From his time at Lawrence Livermore National Laboratory, to his work as a Director at MRI Global, and his most recent efforts as CEO of ImpeDx Diagnostics, Dr. Swiger’s leadership and laboratory […]
